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Abstract: As the number of poorly soluble drugs is increas-
ing, nanocrystals have become very interesting due to
wide rangeof applicationpossibilities. Curcuminwasused
as a model active ingredient in this work. Even though it
has many proven positive effects, due to its physicochemi-
cal issues, its possibilities have not been fully exploited.
The goal of this work was to select optimal conditions
for a top-downmethod for curcumin nanosuspension pro-
duction, and to perform their comprehensive characteri-
zation applying complementary methodologies: dynamic
light scattering, polarization and atomic force microscopy,
thermal analysis, X-ray powder diffraction, antioxidant ac-
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tivity evaluation, release kinetics assessment, and screen-
ing of potential biological effects applying cell viability as-
says onnormal human lungfibroblasts, humanmelanoma
and human adenomacarcinoma cells.
After 30 min of milling, nanosuspensions stabilized by
polysorbate 80 and by its combinations with sucrose
palmitate showed good stability, while curcumin crystal
structure was unaltered. Obtained nanocrystals were well
defined, with average diameter 120–170 nm and PDI of
about 0.25, zeta potential was below −30 mV and pH~5 for
all formulations. Nanodispersions exhibited high antioxi-
dant potential and improved dissolution rate compared to
the corresponding coarse dispersions. Although curcumin
nanodispersions exhibited significant antiproliferative ef-
fect to each cancer cell line, the highest effect was towards
adenocarcinoma cells.
Keywords:nanocrystal; curcumin; top-downmethod,wet-
ball milling
1 Introduction
Nowadays, the majority of newly discovered active phar-
maceutical ingredients are extremely poorly soluble. Such
characteristic results in low bioavailability and obstacles
in reaching the anticipated action site, hindering their per-
formances in vivo. Poorly soluble drugs can be charac-
terized either as grease balls or brick dust molecules [1].
In spite of low water solubility, grease balls have a cer-
tain oil solubility, which enables them to be incorporated
in a lipid-based formulation. On the other hand, brick
dust molecules are poorly soluble both in oils and in po-
lar solvents, which represents a difficulty in their applica-
tion. However, there are several strategies that can be ap-
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plied in order to overcome the problematic physicochemi-
cal properties of activemolecules [2, 3]. Based on evidence
and accumulated knowledge, it has been established that
nanotechnology can enable a therapeutic platform for im-
proved drug delivery [4–9]. These expectations could be
achieved through the specific properties of nanomaterials,
such as size, shape and surface functionalities [10]. Along-
side nanostructured drug delivery systems, which enable
drug solubilization, protection, controlled release and tar-
geting, nanosuspensions, also referred as carrier free for-
mulations [3], represent a promising option for extremely
poorly soluble molecules through improvement of their
bioavailability [11].
Analyzing development of nanomaterials for drug de-
livery, we are witnessing the emergence of a range of dif-
ferent nanosystems. According to the statistics from 2018,
nanosystems have most commonly been used as carriers
for drugs intended for cancer, inflammatory and immuno-
logical diseases - more than 50% of the total number of
approved nanomedicines by the US Food andDrug Admin-
istration. Among them, liposomes are in the first place, fol-
lowed by nanocrystals and nanoemulsions [12–16].
Drug nanocrystals can be defined as submicron crys-
talline particles of the drug (100-1000 nm), with average
diameter usually below 500 nm. They are stabilized by
surfactant, a polymer stabilizer, or their combination [3].
Due to such a small size, some intrinsic properties of
a molecule change dramatically. For example, solubility,
dissolution rate and adhesiveness to the biological mem-
branes are much higher compared to a standard, “macro”
crystal, enabling some specific advantages that can be
achieved in vivo. They increase drug bioavailability, con-
sequently boosting the effectiveness, which is especially
useful for poorly soluble active molecules [2, 3, 17, 18].
Drug nanocrystals are commonly formulated as aque-
ous nanosuspensions, but with some further processing
steps, they can also be transformed to other dosage forms,
suitable for various administration routs (dermal, par-
enteral, ocular...). As very low concentration of surfactant
is applied for nanosuspension formulation, their safety
profile is very favorable [19].
Regarding nanocrystal production, there are 2 possi-
ble approaches: top-down and bottom-up. Top-downmeth-
ods are based on lowering the size of the bulk material
(containing bigger particles) through milling procedures,
whereas bottom-up rely on the opposite mechanism – they
start from a dissolved drug, and nanocrystals are obtained
upon precipitation. Owing to more reliable process con-
trol and easier scale up, top down processes are preferable.
Due to small size, and corresponding large specific sur-
face, nanosuspensions are prone to physical destabiliza-
tion processes (kinetic instability) during storage, so not
only their production, but also stabilization acts as a chal-
lenge [18].
During the recent years, there has been an evident
trend of return to the natural sources of medicinal com-
pounds. With this regard, curcumin, a polyphenol ex-
tracted from the rhizome of the Curcuma spp. (Zingiber-
aceae) represents a phytochemical compelling for thera-
peutic use due to its numerous beneficial properties for
human health. Its antioxidant and anti-inflammatory ac-
tivities are underlined, and anticancer potential is fre-
quently discussed in the literature [20, 21]. Even though
this pleiotropic potential has been well established, cur-
cumin’s in vivo performances are hindered due to low solu-
bility, physicochemical instability, rapid metabolism, and
poor penetration and targeting efficacy. Being a represen-
tative of a demanding active molecule, curcumin is re-
garded as an excellent candidate for application in the
form of nanocrystals.
Therefore, the main goal of this work was to select ap-
propriate process and formulation parameters for a top-
down method for curcumin nanocrystal preparation, and
to conduct a comprehensive physicochemical character-
ization of selected dispersions, with reference to poten-
tial dermal application. Further on, the idea was to assess
the in vitro antioxidant potential, as well as safety profile
and effectiveness of developeddispersions in biological as-
says using 3 cell lines: normal human lung fibroblasts, hu-
man malignant melanoma and human cervical adenocar-
cinoma. The principal idea was to provide sufficient data
on curcumin nanocrystal performances that could pave a
road to some further development and application.
2 Materials and methods
2.1 Materials
For nanosuspension preparation, the following compo-
nents were used: curcumin (Sigma–Aldrich Co; St. Louis,
USA), polysorbate 80 - P80 (Acros Organic, Thermo Fisher
Scientific Company; Geel, Belgium), sucrose palmitate –
SP (Mitsubishi–Kagaku Foods Corporation; Tokyo, Japan),
methylcellulose – MC ( Sigma–Aldrich Co; St. Louis, USA),
and ultra-purified water – W, provided by the Gen Pure
apparatus (TKA Wasseranfbereitungs system GmbH, Nei-
derelbert, Germany). All other chemical used in the exper-
iment were of HPLC grade.
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2.2 Methods
2.2.1 Sample preparation
For sample preparation, a procedure mimicking wet ball
milling was performed. Similar process has already been
reported by Corrias et al. [22]. Briefly, coarse dispersions of
curcumin were prepared using a rotor-stator homogenizer
(UltraTurax, IKA, Staufen, Germany), and further nanon-
ization was conducted in a Cell Disruptor Genie (Scientific
Industries, USA), applying yttrium stabilized zirconium
dioxide beads (Sigmund Lindner, Warmensteinach, Ger-
many; diameter 0.1-0.2 mm) as themillingmedium. Firstly,
the stabilizer solution was prepared in ultra-purified wa-
ter, and then curcumin was added, which was followed by
3-minute homogenization (8000 rpm). After the coarse dis-
persion had been prepared, a defined volume was trans-
ferred to 2ml tubes prefilled with zirconium dioxide beads
(60% v/v). Nanonization was carried out at 3000 rpm,
checking selected properties of the particles at predefined
timepoints: after 10, 30 and60minutes ofmilling. The con-
centration of curcuminwas fixed to 1mg/ml, and the effect
of three different stabilizers (solely and in combinations)
on the milling procedure and stability of obtained disper-
sions was evaluated.
2.2.2 Particle size assessment
In order tomeasure the size of the dispersedphase, photon
correlation spectroscopy was performed using Zetasizer
Nano ZS90 (Malvern Instruments Ltd, Worcester, Malvern,
UK). As sizing parameters, intensity weighted mean diam-
eter (Z-average diameter, Z-ave) and polydispersity index
(PDI) were determined. Prior to measurements, samples
were diluted with ultrapure water (1:100, v/v) in order to
obtain optimal scattering intensity.
2.2.3 Zeta potential measurements
Zeta potential (ZP), as ameasure of particle surface charge
and one of the long-term stability indicators, was deter-
mined through measurements of electrophoretic mobil-
ity of nanoemulsion droplets, using Zetasizer Nano ZS90
(Malvern Instruments Ltd.,Worcester,Worcestershire, UK).
The measurements were conducted immediately upon di-
luting the samples (1:100, v/v) with ultrapure water, at
25∘C, with conductivity adjusted to 50 µS/cm using 0.9%
(w/v) sodium chloride solution.
2.2.4 pH measurements
As an important parameter for curcumin’s stability, pH
of selected samples was also determined (Hanna Instru-
ments Inc, Michigan, USA) at 25∘C.
2.2.5 Polarization microscopy
In order to get an insight into the size and morphology of
the curcumin crystals before and after nanonization, po-
larizationmicroscopywas performed using Carl Zeiss Apo-
Tome Imager Z1 microscope (Zeiss, Göttingen, Germany),
integrated with the AxioCam ICc1 camera.
2.2.6 Thermal analysis
To check the crystalline state of the curcumin powder, and
to verify that crystalline state was not changed after the
nanonization, differential scanning calorimetry (DSC) was
conducted by Mettler DSC 820 apparatus (Mettler Toledo
GmbH Analytical, Giessen, Germany). Air-dried samples
were placed in standard aluminum pans, hermetically
sealed and subjected to the heating program from 25∘C to
200∘C with the heating rate of 2 K/min, under constant
nitrogen flow. An empty aluminum pan served as a refer-
ence.
2.2.7 Atomic force microscopy
For direct observation of the obtained nanocrystals and
morphological evaluation, atomic force microscopy was
performed applying AutoProbe CP-Research SPM (TM
Microscopes-Bruker, Germany). 10 µl of each sample was
directly placed on the circular mica substrate (Highest
Grade V1 AFM Mica Discs, Ted Pella Inc., Redding, Cal-
ifornia, USA) and dried in vacuum. AFM measurements
were performed in air, using noncontact probes Bruker
Phosphorous (n) doped silicon Tap300, model MPP-11123-
10 with Al reflective coating and symmetric tip. Driving fre-
quency of the cantilever was about 300 kHz. Topography
and “error signal” images were captured and analyzed.
2.2.8 X-Ray Powder Diffraction analysis
Selected samples of nanodispersions, as well as their sta-
bilizers, were investigated by the X-Ray Powder Diffraction
(XRPD). Measurements were conducted on Rigaku Smart-
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lab X-ray Diffractometer in θ-θ geometry (the sample in
horizontal position) in parafocusing Bragg-Brentano ge-
ometry using D/teX Ultra 250 strip detector in 1D standard
mode with CuKα1,2 radiation source (U = 40 kV and I = 30
mA). The XRPD patterns were collected in 3-40∘ 2θ range,
with stepof 0.01∘, anddata collection speedof 3∘/min. The
low background single crystal silicon sample holder was
used to minimize the background. Unit cell parameters as
well as average crystallite size and strain values for cur-
cumin are obtained through Whole Powder Patter Fitting
(WPPF) procedure incorporated in PDXL2 integrated X-ray
powder diffraction software (Version 2.8.30; Rigaku Corpo-
ration).
2.2.9 In vitro release/dissolution study using Franz
diffusion cells
In order to be easier for application, selected nanosuspen-
sions and corresponding coarse suspensions were thick-
ened by xantan (1%). The study was performed using
Franz diffusion cells (Gauer Glas, D-Püttlingen, Germany).
In each cell, 1g of the formulation was deposited. The
study was performed in triplicate, applying the protocol
described by Nikolic et al. [23]. More details are provided
in the Supplementary material section.
2.2.10 Evaluation of the antioxidant activity of the
nanocrystal dispersions
For the purpose of antioxidant evaluation, a spectrophoto-
metric free radical scavenging assay - DPPH (2, 2-diphenyl-
1- picrylhydrazyl) was performed. Briefly, in glass cuvettes,
3.6 ml of DPPH solution in methanol (0.1 mM) was mixed
with 400 µL of the test samplewith curcumin. Nanocrystal
dispersions were diluted in ultrapure water in order to ob-
tain the following curcumin concentrations: 0.25, 0.1875,
0.125, 0.0625, and 0.03125 mg/ml. In this manner, the ab-
sorbance values in the range 0.2-0.8 were covered. After
30 minutes of incubation at room temperature, in dark
and under constant shaking (350 rpm), the absorbance of
the samples was recorded at 517 nm, using a spectropho-
tometer (Varian Cary-100 UV–VIS Varian BV, Middelburg,
Netherlands). The blank samplewas preparedwith 400 µL
of the corresponding stabilizer solution. The percentage of
inhibition was calculated using the following equation:
I = [(Ac − As)/Ac] × 100; (1)
where I stands for inhibition percentage, Ac for ab-
sorbance of a blank sample, and As for absorbance of the
test sample. The inhibition percentagewas plotted against
concentrationof the samples, and IC50 values, as themean
value of threemeasurements, was determined by linear re-
gression analysis. Activity of bulk curcuminwas estimated
in the similar manner, following the protocol described by
Nikolic et al. (2018).
2.2.11 LC-MS/MS analysis
Determination of curcumin content during the re-
lease/dissolution study was performed by liquid chro-
matography coupled with mass spectrometry (LC-MS/MS)
technique. For detail on the analytical procedure, please
consult the Supplementary material section.
2.2.12 Biological activity evaluation
Cell lines
For this experimental section, three cell lines were used:
human cervical adenocarcinoma (HeLa), human malig-
nant melanoma (Fem-x), and normal, human lung fibrob-
last (MRC-5), obtained from American Type Culture Col-
lection (Manassas, VA, USA). Cells were maintained in
complete nutrient medium RPMI-1640 (Sigma-Aldrich, St.
Louis, USA), at 37∘C and in humidified atmosphere with
5% CO2. The nutrient medium was supplemented to with
L-glutamine (3 mM), streptomycin (100 mg/mL), peni-
cillin (100 IU/mL), and fetal bovine serum (10%; heat-
inactivated at 56∘C for inactivation of cholinesterases, sys-
tem complement and HEPES (25 mM)). Bicarbonate solu-
tion was used for pH adjustment to 7.2.
Preparation of stock solutions
Firstly, solution of curcumin was prepared in dimethyl sul-
foxide (DMSO) and thendiluted in the cellmedium, so that
the final DMSO concentration was below 0.1%, and cur-
cumin concentration was set to the 600 µg/ml. Nanocrys-
tal dispersions were also diluted in the cell medium giv-
ing the same concentrations. The blank samples (surfac-
tant solution in ultra-pure water) were diluted in the same
manner as the curcumin dispersions. All samples were af-
terwards mixed with the nutrient medium, providing rele-
vant working concentrations.
Treatment of the cell lines
The HeLa (2×103 cells per well), Fem-X (5×103 cells per
well) and MRC-5 (5×103 cells per well) cells were seeded
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into 96-well microtiter plates, and 24 h later, after cell ad-
herence, five different concentrations of the test samples
were added to the wells. The final test concentrations of
curcumin ranged from the 12.5 µg/ml to 200 µg/ml. Corre-
sponding dilutions of the blank formulation were also in-
vestigated. In the control wells, only nutrient mediumwas
added to the cells.
Determination of target-cell survival
Cell survival was determined 48h after the addition
of the test samples, conducting the MTT test, (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide –
MTT; Sigma-Aldrich, St. Louis, USA). MTT was dissolved
in phosphate buffered saline (PBS) pH 7, in the concentra-
tion 5 mg/mL, and filtered through Millipore filters (0.22
µm) prior to use.
Firstly, 10 µL of the MTT solution was added to each
well. The samples were incubated for additional 4 h at
37∘C, with 5% CO2 and humidified atmosphere. Then, 100
µL of the 10% solution of sodium dodecylsulfate – SDS
(Sigma-Aldrich,St. Louis, USA) was added to each of the
wells. The next day, absorbance of the cell medium from
each well was measured at 570 nm, using Multiskan™ FC
Microplate Photometer (Thermo Scientific, USA) and cell
survival (%) was calculated.
The concentration that decreased treated cell survival
by 50% (IC50) was determined from the graph, by numer-
ical analysis of the obtained data. Selectivity index was
calculated by dividing the IC50 value for MRC-5 with IC50
value for Fem-X or HeLa, for each investigated sample.
Three independent experiments were made, each was
performed in triplicate, and results were presented as
mean values ± SD.
2.2.13 Statistical analysis
Physicochemical measurements were performed in tripli-
cates, and results were presented as the mean value of the
observed parameter ± standard deviation. For statistical
significances assessment, Student t-test was performed,
and statistical significance was set at p<0.05.
3 Results and discussion
3.1 Selection of the stabilizers and
optimization of the milling time
In order to provide optimal stabilization of the curcumin
nanosuspension, 3 different stabilizers were evaluated
(polysorbate 80 - P80; sucrose palmitate – SP; methyl
cellulose - MC). They were selected as they represent
different stabilizer types: MC is a polymeric molecule,
P80 is a well-established surfactant, and SP is relatively
new and biodegradable surfactant derived from natural
sources [24]. Several stabilizer concentrations were tested,
as well as some of their mutual combinations, with a view
to obtain the optimal ratio. Firstly, formulations only with
one stabilizer were prepared. Afterwards, in order to re-
duce the concentration of the ethoxylated surfactant, two
combinations of P80 and SP were also tested (P80:SP=4:1
and P80:SP=2:1). Curcumin concentration was fixed to 1
mg/ml, and the ratio curcumin:stabilizer warried as fol-
lowed: 1:1; 1:2.5 and 1:5.
Prior to the nanonization process, the coarse disper-
sions were observed under the polarization light in order
to analyze the features of the curcumin crystals. Dispersed
particles were of irregular shape (isometric and elongated
rod-like) and their size was in the micrometer range, with
broad size distribution (Figure 1).
After the milling procedure had been performed, dis-
persions were packed in glass vials, sealed andmonitored
for any curcumin precipitation for 24 h at room tempera-
ture. To select the optimalmilling time, themilling process
was performed for 10, 30 and 60minutes, and obtained re-
sults in terms of size and size distribution were compared.
For themost promising formulations, the ones that did not
exhibit any precipitation (Table 1, Table 2), size and size
distribution were determined, and their stability was fur-
ther followed.
As presented in the Figure 2, there is an expected trend
of the particle size decrease that follows longer milling
time. Contrastingly, when it comes to the PDI, a different
pattern canbenoticed– if themilling procedure lastsmore
than 30 minutes, PDI increases as well. Similar findings
were reported by Kakran et al. [25]. Such result probably
emanates from the “over processing”phenomenon.Briefly,
during thenanonization, crystals firstly break at the points
called crystal imperfections, where the crystalline struc-
ture is the most fragile. As the process goes further, these
areas become less present, and the crystals become more
perfect. Consequently, the force required for crystal break-
age is higher. Increase in energy input leads to the size re-
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Figure 1: Polarization microscopy images of the coarse dispersions of curcumin: a) F_P80; b) F_P80/SP_4:1; F_P80/SP_2:1
Figure 2: Average particle diameter (a) and polydispersity index (b) of the curcumin dispersions obtained after 10, 30 and 60 minutes of
milling
Table 1: Screening of potential stabilizers and their concentrations for nanosuspension preparation
Stabilizer Stabilizer:CU ratio CU concentration
P80 1:1 1:2.5 1:5 1 mg/ml
Precipitation within 24 h No Yes Yes
SP 1:1 1:2.5 1:5 1 mg/ml
Precipitation within 24 h Yes Yes Yes
MC 1:1 1:2.5 1:5 1 mg/ml
Precipitation within 24 h Yes Yes Yes
P80/SP=4:1 1:1 1:2.5 1:5 1 mg/ml
Precipitation within 24 h No Yes Yes
P80/SP=2:1 1:1 1:2.5 1:5 1 mg/ml
Precipitation within 24 h No Yes Yes
P80 - polysorbate 80; SP – sucrose palmitate; MC – methyl cellulose; CU - curcumin
Table 2: Qualitative and quantitative (%) composition of selected nanosuspensions
Formulation name P80 SP CU W
F_P80 0.1 / 0.1 99.8
F_P80/SP_4:1 0.08 0.02 0.1 99.8
F_P80/SP_2:1 0.067 0.033 0.1 99.8
P80 - polysorbate 80; SP – sucrose palmitate; MC – methyl cellulose; CU - curcumin
412 | I. Nikolić et al.
duction up to a certain point, providing more energy to
break the crystals into smaller ones, and giving enough
time to the stabilizers to attach to the newly formed sur-
face [26]. However, at some point, when the disruption
force becomes equal to the attraction forces of the crys-
talline structure, no further size reduction is possible at
given nanonization conditions [27]. As energy continues
to be delivered to the system, the kinetic energy of the crys-
tals becomes higher, causing aggregation [25]. Similar find-
ings were observed by Rachmawati et al. [28] and Hu et al.
[26] for 2 different methods – high pressure homogeniza-
tion andwetmediamilling. Such event is unfavorablewith
regard to the long-term stability because the particles may
exceed the energy barrier according to the DLVO theory,
and undergo coalescence [29].
It is important to mention that different stabilizers
have distinct effect on the physicochemical stability of the
nanocrystal dispersions, both during shelf-life and when
exposed to the physiological conditions [28, 30]. Not only
the presence of microparticles should be the lowest pos-
sible, but also the size distribution of the dispersed parti-
cles should be homogeneous, regardless the exact value of
the mean particle diameter. This is crucial both for stabil-
ity of the dispersion and imposed bioavailability expecta-
tions [29, 31]. Hence, in the presented experimental setting,
nanonization time of 30minutes was found as the optimal
one.
3.2 Determination of pH and zeta potential
In order to maintain the chemical stability of curcumin in
the formulation, it is of high importance to have a pH in
the acidic region, as it is well known that curcumin un-
dergoes oxidative degradation in the alkaline conditions.
All three selected formulations had pH around 5 (Table 3),
proving the appropriate conditions. Moreover, as a hint
of physical stability of the dispersion, zeta potential was
measured. Even though these formulations are stabilized
by nonionic surfactants, providing steric stabilization, ob-
tained zeta potential values were quite high (Table 3). Val-
ues below −30 mV generally suggest very good physical
Table 3: Determined pH and zeta potential values of the selected
formulations
Formulation pH Zeta potential (mV)
F_P80 5.3 ± 0.1 −30.5 ± 4.9
F_P80/SO_4:1 5.20 ± 0.05 −33.4 ± 3.5
F_P80/SO_2:1 4.9 ± 0.1 −35.1 ± 2.9
stability [32], preventing aggregation and cake formation.
In this case, as nonionic stabilizers were used, obtained
values may be due to pH of the dispersions. Namely, cur-
cumin is prone to keto-enolic tautomerization, and in the
acidic environment, diketo form prevails, being a potent
proton-donor [21]. Accordingly, it may influence the sur-
face electrical properties.
3.3 Atomic force microscopy, thermal
analysis and X-ray powder diffraction
To directly observe obtained curcumin nanocrystals,
atomic force microscopy was performed. It enabled 3D
analysis of the particles, their size and morphology. Sigle
particles as well as the profile of selected ones are de-
picted in the Figure 3. It was noted that, after the nanon-
ization, particles became more homogeneous in size and
shape. However, slight disagreement of the estimated size
obtained after DLS may be attributed to the sample prepa-
ration, and nonspherical shape of the crystals (contrast-
ingly the assumption supporting DLS size estimation) [33].
In addition, it is well known that some stress condi-
tions (such asmilling or exposure to different temperature
conditions) can influence the physical state of the com-
pound, inducing some amorphisation [34]. Such event, in
terms of nanocrystal formulations, may be an undesired
consequence. Therefore, the crystallinity of curcumin dis-
persion was checked before and after the nanonization
with a view to check the physical state and structural orga-
nization of the material, applying DSC measurements and
XRPD.
Bulk material (curcumin before nanonization) exhib-
ited a sharp endothermic peak at 174∘C (Figure 4), which
corresponds to its melting temperature. After the milling,
formulations were subjected to the same analysis. Due to
the possibility of the water evaporation peak to overlap
the curcumin’s melting peak, prior to the analysis, wa-
ter was removed from the samples using a vacuum pump.
Again, there was a visible endothermic peak correspond-
ing to the melting of the curcumin’s crystalline structure,
pointing out that no amorphisation occurred. However, it
was visible that the melting temperatures were shifted to-
wards lower values. Such finding confirmed that at the
nanoscale, some fundamental physicochemical features
of a molecule change (e.g. melting point and solubility).
Assuming spherical shape of a nanocrystal, a linear rela-
tionship has been found between the melting point and a
reciprocal value of the particle size, underlining that melt-
ing point decreases with decrease in the particle size [35].
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Figure 3: 3D atomic force microscopy images of the investigated curcumin nanocrystal dispersions and corresponding height-distance
profiles for selected particles (marked with an arrow): a) F_P80; b) F_P80/SP_2:1; c) and d) F_P80/SP_4:1
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Figure 4: Differential scanning calorimetry thermograms of the curcumin nanocrystal dispersions (a) and bulk curcumin (b)
Tm (D) = Tm0
(︂
1 − βD
)︂
(2)
where D is the particle diameter, Tm and Tmo are melting
temperatures of a nanocrystal and bulk material, respec-
tively, and β a material constant.
Further on, in some succeeding works, it has been es-
tablished that not only size, but also shape has influence
on the melting properties of material [36, 37]. Lu et al. [36]
developed amodel for prediction of size, shape anddimen-
sionality effect on the melting point of nanocrystals:
Tm (D, d, λ)
Tm0
≈ (3 − d) hSb0λ9RD (3)
where D denotes the diameter, d a dimensionality param-
eter (for spherical particles d=0, for cylindrical nanowire
d=1, for thin films d=2), λ a shape parameter (varying from
0 to 3, for spherical particles, cubic particles, cubic and
cylindrical nanowires and thin films λ=1), R is ideal gas
constant, Sbo is the bulk solid-vapor transition entropy,
and h denotes atomic diameter.
Hence, the melting temperature of a crystal decreases
with increasing λ or decreasing D and d.
Some authors hypothesized that shift in the melting
pointwith significantly reduced peak intensitymay be due
to the interactions of curcumin and stabilizing agents dur-
ing the milling procedure [26]. In this case, after the XRPD
analysis, such assumption was not supported, as no inter-
actions were identified (Supplementary material section).
Therefore, obtained lower values of the melting point of
curcumin nanocrystals are due to the changes in the parti-
cle size and shape compared to the bulk material.
As a supporting evidence, XRPD analysis confirms
that curcumin is always present as polymorph 1 in spec-
imens: F_P80, F_P80/SP_4:1, F_P80/SP_2:1 and bulk cur-
cumin (Figures S1-S4, Supplementary material section).
Neither polymorphs 2 and 3, nor amorphous state of cur-
cumin were not detected, even though they were dis-
cussed by Sanphui et al. [38]. Stabilizers palmitate and
polysorbate 80 (Figures S5 and S6, Supplementary mate-
rial section) do not contribute to patterns of curcumin in
F_P80/SP_4:1 and F_P80/SP_2:1. XRPD patterns of here
presented curcumin are quite similar to calculated pat-
tern (from single crystal data) reported by Sanphui et
al. [38] andXRPDpattern reported byReid et al. [39]. Slight
change in unite cell parameters between bulk curcumin
and reference one [39] could be attributed to synthesis pro-
cedure (Table 5). Bulk curcumin is characterized by large
crystallites and low strain. Ball milling provoke important
crystallite size and strain change comparing to bulk cur-
cumin, especially for F_P80. Only in that case specimen
was contaminated with 29% of zirconium oxide originated
from the milling medium (Figure S1, Supplementary mate-
rial section). In F_P80/SP_4:1 and F_P80/SP_2:1 crystallite
size decrease for about 25% comparing to bulk curcumin
and strain increase for about 400% (Table 5)
All reported results indicate that nanonization and
processing under presented experimental condiditions
did not cause amorphization or change in the polymorph
form.
3.4 Short-term physical stability
assessment
In order to check the preliminary physical stability of
obtained dispersions, size and size distribution of the
nanocrystalswas followed for 2weeks.Moreover, each day
samples were visually inspected for any precipitation or
organoleptic alternations (evident change of color or gen-
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Table 4:MTT assay results (concentrations of curcumin (dissolved) and curcumin nanocrystals expressed in µg/ml that induced 50%
decrease in the cell survival (IC50)) and calculated selectivity index of curcumin in a solution and curcumin nanocrystals
Cytotoxicity assessment Selectivity index
Sample MRC-5 Fem-X HeLa Fem-X HeLa
Curcumin (solu-
tion)*
71.17±22.60 70.75±30.89 15.035±0.615 1.01 4.73
F_P80* 40.36±2.86 30.56±11.9 8.81±2.85 1.32 4.58
F_P80/SO_4:1* 40.59±3.17 21.02±0.77 11.36±5.23 1.93 3.57
F_P80/SO_2:1* 34.63±13.65 56.91±33.55 14.46±0.32 0.61 2.39
All data are results of the three independent experiments, each carried out in triplicate.
* Significantly higher anti-proliferative effect towards HeLa, compared to the effect towards Fem-X and MRC-5 cell lines (p<0.05)
Selectivity index is calculated by dividing IC50 obtained for the MRC-5 by IC50 obtained for Fem-X and HeLa cells, respectively.
All data are result of the three independent experiments, each carried out in triplicate.
Table 5: Refined unite cell parameters, average crystallite size* and average strain for: F_P80, F_P80/SP_4:1, F_P80/SP_2:1 and bulk
curcumin. Unite cell parameters for reference curcumin [39] is also present as well as reliability factors of the WPPF refinement Rwp, Rp,
Rexp and S for F_P80, F_P80/SP_4:1, F_P80/SP_2:1 and bulk curcumin
F_P80 F_P80/SP_4:1 F_P80/SP_2:1 Bulk curcumin Reid et al. [39]
a (Å) 12.701(7) 12.7049(18) 12.7063(18) 12.7021(19) 12.6967
b (Å) 7.223(3) 7.2355(6) 7.2351(6) 7.2361(7) 7.1985
c (Å) 19.875(11) 19.886(3) 19.882(3) 19.881(4) 19.9533
β (∘) 95.53(3) 95.475(9) 95.481(8) 95.509(10) 95.124
α=𝛾 (∘) 90 90 90 90 90
V (Å3) 1814.9(17) 1819.7(4) 1819.5(4) 1818.9(5) 1816.393
Average size (nm) 19.1(2) 41.1(2) 37.7(2) 55.06(4) /
Average strain (%) 0.7(2) 0.25(5) 0.28(7) 0.067(15) /
Rwp (%) 6.02 13.05 11.78 19.87 /
Rp (%) 4.58 8.53 7.75 14.63 /
Rexp (%) 5.22 4.11 4.03 3.63 /
S 1.15 3.18 2.92 5.47 /
Figure 5: Short-terms physical stability assessment of the investi-
gated curcumin nanocrystal dispersions
eral appearance of the samples). No agglomerationwas ob-
served (Figure 5) and no precipitation occurred during this
short-term stability check.
3.4.1 In vitro dissolution/release study
Targeting potential dermal application, in order to evalu-
ate the dissolutionproperties of the obtainednanocrystals,
selected dispersions were thickened with 1% of xanthan,
and the experiment was performed applying Franz diffu-
sion cells.
All samples followed Higuchi’s kinetics. Interestingly,
comparing the coarse dispersion to the nanocrystal disper-
sions, completely opposite results were captured. Namely,
in the case of nanodispersions, during the 6h of the exper-
iment, F_P80/SP_2:1 reached the highest release, whereas
the corresponding coarse dispersion exhibited the lowest
release (Figure 6). Obviously, the rank order in the case of
nanodispersion formulations correlated to the measured
diameter of the nanoparticles. Such finding was somehow
expected, as it is well known that decreasing the parti-
cle size, saturation solubility and dissolution velocity in-
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Figure 6: In vitro dissolution/release kinetics of the thickened curcumin nanocrystal dispersions (a) and curcumin coarse dispersions (b)
crease due to the bigger contact surface with the solvent
and higher dissolution pressure [3, 40]. Such behavior can
be explained through the Ostwald– Freundlich equation:
log CsC∞ =
2δV
2.303RTρr (4)
where Cs and C∞ denote saturation solubility and solu-
bility of the material consisting of large particles (respec-
tively), R is universal gas constant, T absolute temperature,
V ismolar volumeof thematerial, δ is interfacial tension, ρ
represents density of the solidmaterial, and r is the radius.
Accordingly, for particles having radius smaller than 1 µm,
solubility rises exponentially when radius decreases.
On the other hand, for the coarse dispersions, particle
sizewas not the limiting feature. A reasonable explanation
of the obtained rank order of the formulations may be the
fact that P80 behaved as a good solubilizer, providing bet-
ter dissolution rate.
In addition, comparing the total dissolved and re-
leased amount of curcumin from the corresponding sus-
pensions, the nanocrystal formulations were significantly
superior in each case, highlighting the beneficial effect of
the nanodispersed systems.
3.5 Antioxidant activity evaluation
To demonstrate the antioxidant scavenging potential of
curcumin nanocrystals, DPPH test was performed. As a pa-
rameter of interest, the concentration that inhibits 50% of
the free radical in the selected experimental settingwasde-
termined (IC50). Also, comparing the results obtainedwith
the bulk curcumin, this test served as a method to check
whether any significant change/decrease in the activity oc-
Figure 7: In vitro antioxidant activity assessment of the investigated
curcumin nanocrystal dispersions: scavenging activity dependence
on curcumin concentration
curred during the processing steps in the nanocrystal dis-
persion preparation.
According to the increasing curcumin concentration,
there was a visible trend of higher scavenging ability. The
IC50 was reached for the curcumin concentration around
0.1 mg/ml. More importantly, all formulations exhibited
approximately the same potency (Figure 7), proving that
the antioxidant activity was not jeopardized by the prepa-
ration steps. However, further experimental work should
beperformed inmore relevant conditions (without organic
solvents) where potential prolonged activity of curcumin
nanocrystals could be evaluated.
3.6 In vitro screening of biological effects
With a view to have an objective insight into the safety
and efficacy of the nanocrystal dispersion, cell cytotoxic-
ity assessment was performed applying 3 cell lines: MRC5
for safety screening, and Fem-X and HeLa for obtaining a
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Figure 8: Cell viability assay: a) MRC-5 cell line; b) Fem-X cell line; c) HeLa cell line. Cells were incubated with several concentrations of
the investigated curcumin nanocrystal dispersions and curcumin solution. Obtained data show cell viability dependence on the curcumin
concentration. Each experiment was repeated three times and the results were presented as the mean value ± SD
Figure 9: Optical density of the cell cultures after the treatment by the investigated samples: a) MRC-5 cell line; b) Fem-X cell line; c) HeLa
cell line. Cells were incubated with several concentrations of the curcumin nanocrystal dispersions and curcumin solution After 48 hours
of incubation, MTT reagent was added. Obtained data show optical density of the cell cultures (570 nm) for the selected sample concentra-
tions. Each experiment was repeated three times and the results were presented as the mean value ± SD
clue on efficacy. Having in mind prospective dermal appli-
cation, efficacy aspects onMRC-5 were recognized asmore
important.
Regarding MRC-5 and Fem-X, no safety issues were
found for the blank samples, whereas HeLa cells were af-
fected evenby the blank samples, but in thehigher concen-
trations (Supplementarymaterial section). However, based
on overall assessment, it can be seen that HeLa cells were
generally more susceptible to the cytotoxic effect, as the
calculated IC50 values (Table 4) are significantly lower in
the case of HeLa compared to other two cell lines. Sim-
ilar results have already been published with curcumin-
loaded nanoemulsions [20]. Moreover, curcumin exhib-
ited an effect to each cell line, but in the nanocrystal form
the concentration dependent cell viability decay was less
sharp (Figure 8, Figure 9), especially for MRC5 and FemX.
Considering selectivity index as a measure of discrimina-
tive ability of the formulation to perform cytotoxic effect,
it was found that HeLa cells were visibly more affected
compared to the Fem-X cells (Table 4). More importantly,
even though the tested formulations are nanosuspensions,
which is unusual in terms of cytotoxicity assessment, no
morphological changes were captured (data not shown)
compared to the pure curcumin solution. However, IC50
values in the case of curcumin nanosuspensions are sig-
nificantly higher. Therefore, we may not exclude some po-
tential mechanical damage, due to particle deposition.
4 Conclusion
Based on the overall assessment, it has been shown that
the presentedmethod, mimicking the wet ball milling pro-
cedure (butwith significantly lower sample amounts), was
appropriate for the nanocrystal dispersion preparation for
preliminary studies. It is noteworthy that small-scale pro-
duction units are extremely important in cases when only
limited amounts of active pharmaceutical ingredient are
available (e.g. with newly discovered active compounds).
With this regarded, presented approach might represent a
good option in preclinical drug evaluation.
It was depicted that the optimal particles in terms of
size and size distributionwere obtained after 30minutes of
milling, under the speed of 3000 rpm. However, it is note-
worthy that the particles’ fineness is a function of a particle
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shape and the nature of a specific molecule [24]. Selected
dispersions stabilized by P80 and its combinations with
SPwere stable, and curcumin’s antioxidant ability was un-
altered after the nanonization. Moreover, in cell viability
assay, significant anticancer effect of curcumin and cur-
cumin nanocrystals was observed.
The size of obtained particles is comparable to some
lipid-based system that have already been developed
and investigated for curcumin delivery [23, 41]. Due to
significantly lower surfactant concentration, safety pro-
file of nanosuspensions is highly improved compared to
other systems with nanostructure, while biological perfor-
mances remainunaltered. Therefore, the application areas
of nanosuspensions are broader.
It should be underlined that many research publica-
tions dealt with curcumin nanocrystals in terms of prepa-
ration method and physical aspects [26, 28, 30, 42–44].
However, little has been done to evaluate the biological
performances of this pleiotropic molecule after the pro-
cessing, even though its susceptibility to physicochemical
degradation is well known. Therefore, a comprehensive
approach in the presented work should provide some new
insights. Still, further considerations should be taken into
account in order to fully characterize these systems.
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Supplementary Materials
X-ray powder diffraction analysis
Figure S1: XRPD pattern for F_P80. Reference XRPD patterns for curcumin (card number 00-066-1420; ICDD (PDF-2 Release 2016 RDB)) and
zirconium oxide (card number 01-081-1544; ICDD (PDF-2 Release 2016 RDB)) in blue and red are below the experimental pattern. Specimen
contains 71(1)% of curcumin and 29(1)% of zirconium oxide.
Figure S2: XRPD pattern for F_P80/SP_4:1. Reference XRPD pattern for curcumin (card number 00-066-1420; ICDD (PDF-2 Release 2016
RDB)) in blue is below the experimental pattern.
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Figure S3: XRPD pattern for F_P80/SP_2:1. Reference XRPD pattern for curcumin (card number 00-066-1420; ICDD (PDF-2 Release 2016
RDB)) in blue is below the experimental pattern.
Figure S4: XRPD pattern for bulk curcumin. Reference XRPD pattern for curcumin (card number 00-066-1420; ICDD (PDF-2 Release 2016
RDB)) in blue is below the experimental pattern.
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Figure S5: XRPD pattern for sucrose palmitate.
Figure S6: XRPD pattern for polysorbate 80.
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In vitro dissolution/release study
In order to be easier for application, selected nanosuspen-
sions and corresponding coarse suspensions were thick-
ened by xanthan gum (1%). The study was performed us-
ing Franz diffusion cells (Gauer Glas, D-Püttlingen, Ger-
many). In each cell, 1g of the formulation was deposited.
The study was performed in triplicate.
As acceptor medium ethanol 50% v/v was used
(Nikolic et al., 2018). Each cell receptor chamber was filled
with ethanol 50 % v/v (chamber volume: 12 mL; effec-
tive diffusion area: 2.01 cm2), preheated to 32∘C. Polycar-
bonate membranes (Nuclepore™, Whatman, Maidstone,
United Kingdom; pore dimeter: 0.1 µm), activated in the
same ethanol solution during 12-hours period, were care-
fully placed on top of the receiver compartment, and then
the donor and acceptor chamber were fastened. Any ex-
isting air bubbles were removed. The donor chamber was
filled with 1 g of the samples being investigated, and after-
wards covered with silicone film (ParafilmTM, USA) to pre-
vent evaporation and loss of the formulation during sam-
pling. Cells were placed in the water bath where the tem-
perature of 32∘Cwasmaintained through thewhole experi-
ment. Acceptor phasewas under continuousmagnetic stir-
ring at 500 rpm. Release study was performed for 6 hours.
Aliquots of 0.6 µL of the acceptor phase were withdrawn
at 6 time points (0.5 h, 1h, 2h, 3h, 4h and 6h), and then
replaced with the same volume of fresh and thermostated
ethanol solution. LC-MS/MS technique was used for deter-
mination of curcumin content. Aiming to find the model
that best describes the drug liberation profile from investi-
gated samples, cumulative amounts of curcumin per unit
area were evaluated through several kinetic models.
LC-MS/MS analysis
Determination of curcumin content during the re-
lease/dissolution study was performed by liquid chro-
matography coupled with mass spectrometry (LC-MS/MS)
technique Liquid chromatographic system with Accela au-
tosampler and the pump (Thermo Fisher Scientific, San
Jose, CA) was applied, and analysis was conducted un-
der established separation conditions. Xterra® MS C18
column (3,5 µm 2,1×150 mm; Waters Corporation, Ireland)
was used for the separation, at 25∘C. A mobile phase con-
sisting of acetonitrile and 0.1% formic acid aqueous so-
lution (70:30 v/v) was used for isocratic elution, at flow
rate of 0.3 mL/min, and run time of 5 minutes. Mass anal-
yses were conducted on TSQ Quantum Access MAX triple
quadrupole mass analyzer equipped with electrospray
ionization (ESI) source and high-purity nitrogen as neb-
ulizing gas. Selected reaction monitoring (SRM) for data
collecting was in positive mode, and ESI source and mass
spectrometry parameters were at following values: spray
voltage - 5000 V; vaporizer temperature - 400∘C; sheath
gas pressure - 30 units; ion sweep gas pressure - 0 units;
auxiliary gas - 15 units; ion transfer capillary temperature
- 250∘C; capillary offset - 35 units; skimmer offset - 0 units;
m/z 369,2→ 177,0; collision energy – 22 V; peak width -
0.7; scan time - 200 ms. The data were processed through
Xcalibur software v 2.1.0.1139 (Thermo Fisher Scientific).
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In vitro screening of biological effects
Figure S7: Cell viability assay: a)MRC-5 cell line; b) Fem-X cell line; c) HeLa cell line. Cells were incubated with several concentrations of
the corresponding blank samples. Obtained data show cell viability dependence on the blank sample concentration. Each experiment was
repeated three times and the results were presented as the mean value ± SD.
